Lombard Odier updated its dollar outlook, forecasting 0.85 Swiss francs per dollar, up from 0.83. The bank attributes this stronger dollar view to robust US economic growth and reduced market concerns about Federal Reserve independence. Its 12-month EUR/USD forecast remains at $1.09. In June, Lombard Odier shifted its recommended dollar allocation from underweight to neutral, maintaining a neutral stance against emerging-market currencies. This outlook signals confidence in the dollar's strength amid evolving economic conditions.
Lombard Odier's updated dollar and euro outlook provides context for cryptocurrency market activity on Pluang. For readers following digital assets, here is Pluang's market snapshot as of Oct 20, 2026 04:42 WIB: Among 50 major cryptocurrencies, 46 rose and 3 fell today. Polkadot (DOT) gained 7.63% to Rp20.410 with a typical hold time of 121 days but saw 83% sell orders, contrasting with Cosmos (ATOM) which rose 7.33% to Rp31.274 with a shorter hold time of 61 days and 76% buy orders. MultiversX (EGLD) increased 6.13% to Rp64.853, with a hold time of 86 days and a more balanced order activity of 43% sell versus 57% buy.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
